Bio-Rad

The court also ordered a new trial to determine if 10x's products infringe reconstructed patents held by Bio-Rad Laboratories.

The overall revenue decrease was buoyed by 19 percent year-over-year growth in Life Science segment revenues due to strong PCR-related sales.

According to the registry's first dataset, more than 65 million tests have been manufactured and shipped across the US.

The listing enables assay developers and testing labs in the US to access the instrument for COVID-19 testing, the firm said.

10x asked the US District Court for the Northern District of California to dismiss a suit, while another district court judge denied a 10x motion to dismiss.

Bio-Rad said it is withdrawing its previously issued annual revenue guidance given the uncertainties regarding the duration and impact of the COVID-19 pandemic.

The triplex assay can be used on the firm's QX200 or QXDx Droplet Digital PCR systems to process 93 patient samples per run.